Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...
Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo
Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...
Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...
Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China
Eisai (TYO: 4523) China, operating through its subsidiary Eisai (Liaoning) Pharmaceutical Co., Ltd., announced a...
Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...
Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...
Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...
Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes
A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...
Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance
Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...
China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs
The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...
Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal
Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...
Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite
Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...
Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production
Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...
AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy
AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...
Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD
Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...
Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...
Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices
The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...
GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities
GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...
Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound
Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...